DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more

DiaSys Highlights Wide Range of Reagents and Instrumentation Products

By LabMedica International staff writers
Posted on 25 Jul 2023

Image: DiaSys is presenting a scientific poster on procalcitonin at AACC 2023 (Photo courtesy of DiaSys)

DiaSys Diagnostic Systems (Holzheim, Germany) is presenting its products at AACC 2023 with a booth to support visitors in finding the right tools and services to meet the growing needs of their lab. DiaSys is offering a closer look into its comprehensive portfolio of clinical chemistry analyzers, reagents, calibrators, and controls, and is also presenting a scientific poster on procalcitonin.

Serum procalcitonin (PCT) levels represent a sensitive marker for severe and systemic bacterial infections. PCT is primarily produced in thyroid C cells as a precursor of calcitonin but is expressed in nearly all tissues by stimulation of interleukins and bacterial endotoxins. In healthy individuals, PCT concentrations are usually below 0.05 ng/mL, and a significant increase of PCT up to a thousand-fold appears within a few hours in patients with severe and systemic bacterial infections. DiaSys Procalcitonin FS is a fluid-stable, particle-enhanced immunoturbidimetric assay with outstanding onboard and calibration stability, providing a convenient workflow on clinical chemistry analyzers. Procalcitonin FS determination in serum and plasma within the measuring range of 0.2 ng/mL to 50 ng/mL can be performed with high precision at clinical cut-off levels for sepsis. The performance is complemented by high tolerance to endogenous interferents and various therapeutics used in sepsis management. Procalcitonin FS shows a good correlation to established methods. Results from ring trials and a publication demonstrate the strengths of the assay.

Among its other products being highlighted at the show is the DiaSys CRP FS liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls that allow true differentiation of borderline cases. DiaSys has recently extended its cardiovascular risk assessment portfolio with two innovative new reagents, HDL-c direct FS and LDL-c direct FS. Both are homogenous assays for direct determination. DiaSys has also expanded the application range for its Total bile acids 21 FS reagent and now offers the assay for use in serum and stool samples. DiaSys Total bile acids 21 FS for serum and stool samples may be conveniently applied on automated analyzers commonly available in any clinical laboratory and are highly time-saving.

Related Links:
DiaSys Diagnostic Systems